Loading...
Loading...
Cytori Therapeutics, Inc.
CYTX announced that the first
patient has been enrolled and treated in the ADRESU trial, a late phase,
physician-initiated Japanese clinical trial to study the efficacy and
safety of Cytori Cell Therapy™ in men with urinary incontinence after
prostatic surgery for prostate cancer or benign prostatic hypertrophy.
ADRESU is a multicenter, 45 patient open label controlled trial of the
ECCI-50 cellular therapeutic and is based on promising pilot trial data
published in the International
Journal of Urology in 2014. Details of the pilot trial can be found
on clinicaltrials.gov
and the MHLW
website. The primary endpoint for the ADRESU trial will be the
number of
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in